Thermo Fisher Scientific, Inc. (TMO)
Thermo Fisher Scientific, Inc. is a global leader in scientific research and laboratory equipment, providing innovative products and services for life sciences, healthcare, and applied markets. Founded in 2006 through the merger of Thermo Electron and Fisher Scientific, the company specializes in laboratory instrumentation, analytical instruments, reagents, and consumables used in various science and clinical applications. It supports research institutions, pharmaceutical companies, and government agencies with solutions that advance scientific discovery and improve health.
Dividend History
Investors can expect a dividend payout of $0.43 per share, scheduled to be distributed in 25 days on October 15, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 15, 2025 | $0.43 | 2025-09-15 | 2025-09-15 |
| July 15, 2025 | $0.43 | 2025-06-13 | 2025-06-13 |
| April 15, 2025 | $0.43 | 2025-03-14 | 2025-03-14 |
| January 15, 2025 | $0.39 | 2024-12-13 | 2024-12-13 |
| October 15, 2024 | $0.39 | 2024-09-13 | 2024-09-13 |
Dividends Summary
- Thermo Fisher Scientific, Inc. has issued 55 dividend payments over the past 13 years
- The most recent dividend was paid 67 days ago, on July 15, 2025
- The highest dividend payed out to investors during this period was $0.43 per share
- The average dividend paid during this period was $0.22 per share.
Company News
The global Carcinoembryonic Antigen (CEA) market is projected to grow from $2.17 billion in 2025 to $3.45 billion by 2033, driven by rising cancer prevalence and advances in diagnostic technologies.
RBC Capital upgraded Bio-Techne to Outperform, raising price target from $61 to $73, citing potential for mid-single-digit revenue growth and attractive valuation after recent market selloff.
William Blair analyst Matt Larew initiated coverage of Thermo Fisher Scientific with an outperform rating, highlighting the company's competitive advantages and potential for recovery in the biopharma segment despite current market softness.
The article discusses research reports on Thermo Fisher Scientific, Micron Technology, and KLA. Thermo Fisher is benefiting from new product launches and strong financial performance, while Micron is seeing improved market conditions and rising demand for memory and storage. KLA is performing well due to strong wafer inspection business and AI adoption, though it faces some headwinds.
The UK's competition regulator has cleared Thermo Fisher Scientific's $3.1 billion acquisition of Swedish biotech firm Olink Holding.
